$126,250
median · per year, annualized USD
$142,000
median · per year, annualized USD
Associate Director, Drug Safety
Drug Safety Associate III
Drug Safety Associate II
Senior Specialist I, Patient Safety & Pharmacovigilance (Clinical Trial Safety Operations)
Specialist I, Patient Safety and Pharmacovigilance Operations
Associate Director, Regulatory Affairs (on-site)
Associate Director, Regulatory Affairs Strategy - Genetics Medicine
Associate Regulatory Affairs Strategy Director (Oncology)
Regulatory Affairs Senior Manager, Regulatory Information & Content Management
Regulatory Affairs- Senior Manager, Globalization (Registrations)
Associate Director, Regulatory Affairs - Biosimilars (US)
Senior Regulatory Affairs Manager – Digital Solutions (on-site)
Associate Director Regulatory Affairs – Vascular (on-site)
Associate Director, Regulatory Affairs
Sr Manager Regulatory Affairs- LATAM
| Company | Median | Roles |
|---|---|---|
Exelixis
|
$142,000 | 2 |
Corcept Therapeutics
|
$98,375 | 2 |
Iambic Therapeutics, Inc
|
$184,500 | 1 |
| Company | Median | Roles |
|---|---|---|
Abbott
|
$149,500 | 18 |
BD
|
$90,646 | 12 |
Regeneron
|
$144,600 | 11 |
Johnson & Johnson
|
$103,325 | 9 |
Stryker
|
$115,650 | 6 |
Gilead Sciences
|
$164,288 | 5 |
Corcept Therapeutics
|
$151,450 | 3 |
Iovance Biotherapeutics
|
$150,000 | 3 |
| Location | Median | Roles |
|---|---|---|
| San Francisco | $182,500 | 5 |
| Boston | $172,500 | 7 |
| New York | $135,000 | 5 |
| Denver | $97,500 | 3 |
The median for Pharmacovigilance is $126,250 per year (typically $120,350–$157,750), versus $142,000 for Regulatory Affairs ($103,463–$172,500). That puts Regulatory Affairs about 12% ahead at the median.
Both figures are computed live from active listings on JobsRadar and normalized to annualized USD, so Pharmacovigilance and Regulatory Affairs are compared on equal terms regardless of the currency each role was originally posted in. Only roles that publish a salary range feed the medians; numbers refresh every few hours as new roles post and older ones close, so this comparison reflects the market right now rather than a fixed survey. Use it as a directional benchmark when weighing one path against the other.